Posted on July 19, 2012
Deadline: September 6, 2012 (Letters of Intent)

Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Degeneration Announce Request for Proposals

The Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Degeneration have announced a Request for Proposals designed to accelerate and support drug discovery for frontotemporal dementia (FTD) and related dementias.

Priority areas for this program include target validation studies; development and testing of novel high throughput screening assays; medicinal chemistry on lead compounds; identification and in vitro testing of potentially disease modifying lead compounds; ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds; testing of lead compounds in a relevant animal model for preclinical proof of concept; development of biomarkers to accelerate drug development and early diagnosis; and innovative pilot clinical trials. (Please note: This funding will not support applications for basic research.)

Applications may be submitted by nonprofit academic institutions and for-profit biotechnology companies, both public and private, worldwide. (The foundation provides funding to biotechnology companies typically through program-related investments.)

The program will award grants of up to $150,000 for one year, with the possibility of follow-on funding.

Submission of a Letter of Intent is required prior to September 6, 2012. The deadline date for applications is September 20, 2012.

Visit the ADDF Web site for the complete RFP and the online application process.

Contact:
Link to Complete RFP

Primary Subject: Aging
Geographic Funding Area: National

Looking for additional funders in the field of Aging?
Foundation Directory Online allows you to search the entire universe of U.S. grantmakers. Target your search by field of interest, type of support, geographic focus, and more. Find the plan that's right for you»